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ABSTRACT  33 
In pituitary adenomas, early recurrences and resistance to conventional 34 
pharmacotherapies are common, but the mechanisms involved are still not understood. The 35 
high expression of epidermal growth factor receptor 2 (HER2)/extracellular signal-regulated 36 
kinase (ERK1/2) signal observed in human pituitary adenomas, together with the low levels 37 
of the antimitogenic transforming growth factor beta receptor 2 (TBR2), encouraged us to 38 
evaluate the effect of the specific HER2 inhibition with trastuzumab on experimental 39 
pituitary tumor cell growth and its effect on the antiproliferative response to TGFB1. 40 
Trastuzumab decreased the pituitary tumor growth as well as the expression of ERK1/2 and 41 
the cell cycle regulators cyclin D1 and CDK4. The HER2/ERK1/2 pathway is an attractive 42 
therapeutic target, but its intricate relations with other signaling modulators still need to be 43 
unraveled. Thus, we investigated possible cross-talk with TGFB signaling, which has not yet 44 
been studied in pituitary tumors. In tumoral GH3 cells, co-incubation with trastuzumab and 45 
TGFB1 significantly decreased cell proliferation, an effect accompanied by a reduction in 46 
ERK1/2 phosphorylation, an increase of SMAD2/3 activation. In addition, through 47 
immunoprecipitation assays, a diminution of SMAD2/3-ERK1/2 and an increase SMAD2/3-48 
TGFBR1 interactions were observed when cells were co-incubated with Trastuzumab and 49 
TGFB1. These findings indicate that blocking HER2 by trastuzumab inhibited pituitary tumor 50 
growth and modulated HER2/ERK1/2 signaling and consequently the anti-mitogenic 51 
TGFB1/TBRs/SMADs cascade. The imbalance between HER2 and TGFBRs expression 52 
observed in human adenomas and the response to trastuzumab on experimental tumor 53 
growth, may make the HER2/ERK1/2 pathway an attractive target for future pituitary 54 
adenoma therapy. 55 
 56 
 57 
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INTRODUCTION 58 
 Pituitary adenomas occur in around 10-15% of all intracranial neoplasms, but only a 59 
few of these are symptomatic according to estimations from various clinical studies (Asa and 60 
Ezzat 1998; Kaltsas, et al. 2005; Tomita and Gates 1999). Although the vast majority are 61 
benign, between 25 and 55% of pituitary adenomas are invasive, with some exhibiting 62 
clinically aggressive behavior (Ironside 2003; Kaltsas and Grossman 1998). The initial 63 
treatment of pituitary adenomas is based on protocols designed for each tumor type. 64 
Dopamine agonists have become the initial treatment for most patients with prolactin-65 
secreting tumors, whereas for growth hormone‑producing tumors surgical resection is the 66 
first-line therapy, while somatostatin analogs are used in patients with large tumors. 67 
However, 20 % of patients are refractory to these medical treatments (Di Ieva, et al. 2014). 68 
 In normal pituitary tissue, the stimulatory and inhibitory growth signals are finely 69 
regulated, with alterations in these being directly or indirectly associated with tumorigenesis. 70 
The transforming growth factor beta 1 (TGFB1) and epidermal growth factor (EGF) have 71 
opposite functions but play essential roles in tumor development by converting them into 72 
attractive therapeutic targets (Yarden and Sliwkowski 2001).  The human EGF receptor 73 
family consists of four members (HER/ERBB1-4) (Roskoski 2014), with the HER receptors 74 
having of an extracellular domain, a single hydrophobic transmembrane segment, and an 75 
intracellular domain with protein kinase activity (Dworakowska, et al. 2009). Dimerization of 76 
the HER receptors leads to the induction of kinase activity, which as a result a number of 77 
tyrosine residues at the C terminal end of the HER molecules become phosphorylated. The 78 
two major signaling pathways activated by HER receptors are the MEK/ERK and PI3K-AKT 79 
pathways (Yarden and Sliwkowski 2001), which both participate in cell proliferation, 80 
angiogenesis, cell adhesion, cell motility and tumorigenesis (Seshacharyulu, et al. 2012). 81 
Certain components of these pathways may be activated/inactivated by mutations or 82 
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epigenetic silencing, and dysregulation of the components of these cascades can contribute to 83 
resistance to other pathway inhibitors and chemotherapeutic drug resistance (McCubrey, et 84 
al. 2012). In addition, the MEK/ERK and PI3K/AKT cascades are often activated by genetic 85 
alterations in upstream signaling molecules such as receptor tyrosine kinases. In this way, 86 
several malignancies are associated with the mutation or increased expression of members of 87 
the HER family, including lung, breast, stomach, colorectal, head, neck, and pancreatic 88 
carcinomas, as well as glioblastomas (Roskoski 2014).  HER2 is a more potent oncoprotein 89 
than the other HERs, and thus blocking their action might inhibit a myriad of mitogenic 90 
pathways affecting the HER2-expressing tumor cells (Onishi, et al. 2016). Although several 91 
new strategies are currently being developed trastuzumab (a drug designed to block the 92 
receptor HER2) has been the first to attain clinical use, mainly for the treatment of metastatic 93 
breast cancer (Baselga, et al. 1996; Cobleigh, et al. 1999). 94 
The expression of HER2 has been reported in pituitary tumors (Ezzat, et al. 1997; 95 
Nose-Alberti, et al. 1998; Roncaroli, et al. 2003), including prolactinomas (Vlotides, et al. 96 
2009), and it has been demonstrated that overexpression of constitutively active HER2 97 
markedly induces PRL expression and secretion as well as cell growth in rat GH3 lactotroph 98 
tumor cells, effects that are blocked by Lapatinib, a dual tyrosine kinase inhibitor of both 99 
epidermal growth factor receptors HER1 and HER2 (Fukuoka, et al. 2011). For signaling 100 
pathways activated by HER2, there are studies showing increases in MEK/ERK activity in 101 
pituitary tumors (Cakir and Grossman 2009). However, although the MEK/ERK signaling 102 
pathway plays a central role in the regulation of cell proliferation, differentiation and 103 
survival, its exact functional relevance in complex signaling network, pituitary tumorigenesis 104 
and resistance to conventional medical treatments is not fully understood, but it may enable 105 
the development of attractive novel strategies for treating common tumors. 106 
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It is well known that the MEK/ERK is not a unidirectional cascade of protein kinases, 107 
but forms a complex signaling network with many interactions including inhibitory cascades. 108 
Recently, we demonstrated that the TGFB1-antimitogenic effect in pituitary tumor cells was 109 
attenuated by the MEK/ERK1/2 pathway via modulating SMAD2/3 phosphorylation (Petiti, 110 
et al. 2015).  TGFB1 signaling is mediated by TGFB type 1 receptor (TBR1) and TBR2. 111 
Upon TGFB binding, the TBR2 receptors activate the TBR1 receptors, inducing 112 
phosphorylation of mothers against the decapentaplegic homologs SMAD2 and SMAD3 113 
which form trimers with Smad4 that translocate into the nucleus, where they regulate the 114 
expression of genes that control cell cycle progression (Kang, et al. 2009). 115 
One of the principal obstacles to the development of new antitumoral therapies is that 116 
the inhibition of a unique signaling pathway essential for the cell survival is a 117 
pharmacological strategy made ineffective due to the tumoral cells utilizing alternative 118 
cascades and promoting a paradoxical enrichment of resistant cells. In this sense, the study of 119 
the crosstalk between the signals from HER and TBRs in pituitary tumors might permit a 120 
better understanding of the altered balance between the positive and negative regulators that 121 
control the pituitary tumor growth which may condition the therapeutic response. The 122 
HER/ERK1/2 pathway is an attractive therapeutic target as an alternative medical therapy for 123 
pituitary tumors. In order to safely choose the candidate drugs, their intricate relations, 124 
positive and negative feedback loops and signaling modulators must be thoroughly 125 
understood. In the present study, our objectives were to determine the effect of the specific 126 
HER2 receptor inhibitor trastuzumab on pituitary tumor growth, and to evaluate its impact on 127 
the antiproliferative response to TGFB1.  128 
 129 
 130 
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MATERIALS AND METHODS  131 
Human pituitary tissues and tumors 132 
The study group included 20 patients diagnosed with pituitary adenomas from 133 
Hospital Córdoba, Sanatorio Allende or Clínica Reina Fabiola, Córdoba, Argentina in the 134 
period 2004-2015. Pituitary tumors were obtained from consented patients who had not been 135 
treated with radiotherapy by trans-sphenoidal surgery after full endocrine preoperative 136 
evaluation. The fresh human pituitary adenoma tissue at the time of surgery was obtained 137 
from 12 functioning adenomas (4 PRL-secreting, 6 GH-secreting and 2 ACTH-secreting 138 
tumors) and 8 non-functioning adenomas. The samples were processed for 139 
immunohistochemical analysis (Table 1 and Table 2). In addition, a group of tumor samples 140 
were processed for western blot. Non-tumor human adenohypophyses (n=6) were obtained 141 
from autopsies from patients with no evidence of endocrine abnormality and examined 142 
histologically. The present project was approved by the Ethics Committee (Repis N° 143 
37/2014). 144 
 145 
Animal model 146 
Three-month-old Fischer-344 male rats were bred and housed at the Animal Research 147 
Facility of the INICSA-CONICET-School of Medicine, National University of Córdoba, 148 
under controlled temperature (21±3 °C) and lighting conditions (14 h light:10 h darkness 149 
cycle), with free access to commercial rodent food and tap water. Forty-three rats were 150 
randomly assigned to four groups: Group C (n=13): intact animals as control; Group E 151 
(n=13): intact animals treated with estradiol benzoate pellets (30 mg, Sigma–Aldrich, St. 152 
Louis, MO, USA), as described by Sahores et al. (Sahores, et al. 2013), for 45 days to induce 153 
a PRL pituitary tumor development (Asa and Ezzat 2002); Group T (n=4): animals treated 154 
with trastuzumab 6 mg/kg (Herceptin, Roche) during 15 days; Group E+T (n=13): during the 155 
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last 15 days before the end of the estradiol treatment, the rats received trastuzumab. The 156 
treatments with trastuzumab consisted of two intraperitoneal injections given once a week 157 
following protocols previously reported (Eryilmaz, et al. 2015; Guler, et al. 2009; Hendry, et 158 
al. 2016).  159 
All animals were treated in agreement with the Guide for the Care and Use of 160 
Laboratory Animals, published by the United States National Institutes of Health (1996), and 161 
experiments were approved by the Institutional Animal Care Committee of the School of 162 
Medicine, National University of Córdoba. 163 
 164 
Immunohistochemistry  165 
Paraffin-embedded pituitary glands were processed by immunohistochemistry for 166 
HER2, pHER2, TBR1, TBR2, and Ki67. The sections were blocked and incubated ON with 167 
anti-HER2 (1:300: Dako, Glostrup, Denmark), anti-pHER2 (1:300; Santa Cruz 168 
Biotechnology, Dallas, TX, USA), anti-TBR1 (1:200; Santa Cruz Biotechnology, Dallas, TX, 169 
USA), anti-TBR2 (1:200; Santa Cruz Biotechnology, Dallas, TX, USA) or anti-Ki67 (1:75; 170 
BD Biosciences, San Jose, CA, USA) at 4 °C. The sections were then incubated with 171 
biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA, USA) and 172 
streptavidin (Dako, Glostrup, Denmark). The slides from three animals of each experimental 173 
condition were photographed in randomly chosen fields at 400X. The quantification of the 174 
expressions was assessed by subsequent manual counting of positive and negative cells per 175 
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Detection of apoptosis by DNA nick-end labeling 181 
Nick-end labeling was detected using the TUNEL technique, as previously reported 182 
(Palmeri, et al. 2009), following  the manufacturer’s protocol (In Situ Cell Death Detection 183 
Kit; Roche). The slides were observed using a Zeiss Axiostar plus microscope at 400x. 184 
 185 
Cell culture 186 
The rat GH3 lactosomatotroph pituitary tumor cell line (ATCC®-BAA-1926
TM
) was 187 
used as an in vitro pituitary tumoral model (McIntyre, et al. 2004). The cells were cultured in 188 
Ham’s F-12 Nutrient Mixture medium supplemented with fetal bovine and horse serum, and 189 
antibiotics. After 3 days of culture and with a confluence of 70%, the cells were submitted to 190 
different experimental protocols. Cell cultures were treated with TGFB1 (4 ng/ml, Sigma; St 191 
Louis,USA),  Trastuzumab (100ug/mL) or the combination of both factors for 30 min or 24 h.  192 
Flow cytometry staining for detection of Ki67 193 
To analyze GH3 proliferation by Ki67 detection, the cells were detached using TrypLE™ 194 
Express (Gibco, NY, USA), washed twice with PBS and fixed overnight with ice-cold 70% 195 
ethanol. After washing, cells were incubated with anti-Ki67 (1:75; BD Biosciences, San Jose, 196 
CA, USA) at 37°C for 45 min, followed by incubation with secondary antibody Alexa-Fluor 197 
488 (1:1000; Invitrogen, Carlsbad, California, USA) for 1h at 37°C. Finally, GH3 cells were 198 
suspended in PBS and run on a flow cytometer (FACSCanto™ II, BD Biosciences). The data 199 
obtained was analyzed by FlowJo V10 software (Tree Star,Inc, Ashland, OR, USA). 200 
 201 
Immunocytochemical detection of BrdU uptake  202 
GH3 cells at the DNA-synthesizing stage were identified by the immunocytochemical 203 
detection of BrdU. After of stimulation with the different reagents, BrdU (200nM) was added 204 
for an additional 4h. The cells attached to coverslips were fixed in 4% formaldehyde in PBS 205 
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for 2h at room temperature (RT) and BrdU incorporation detection was performed as 206 
described by Ferraris  and co-workers (Ferraris, et al. 2014)  207 
 208 
Immunoprecipitation 209 
Protein extraction of tumoral pituitary cells (1 mg of protein) was carried out 210 
according to previous protocols (Sosa Ldel, et al. 2013), which was then subjected to 211 
immunoprecipitation using specific anti-pSMAD2/3 (5µg/mL, Santa Cruz Biotechnology, 212 
Dallas, TX, USA) or Trastuzumab (5µg/mL). The immune complexes were adsorbed and 213 
precipitated using Protein A-Sepharose beads (Sigma–Aldrich, St. Louis, MO, USA), washed 214 
3 times with lysis buffer and denatured by boiling for 5 min in the sample buffer. Parallel 215 
immunoprecipitations were performed using a non-immune goat serum, which verified the 216 
specificity of the bands detected by western blotting using anti-TBR1 (1:200), anti-217 
pSMAD2/3 (1:1000 Cell Signaling, Massachusetts, USA), and anti-pERK1/2 (1:1000 Cell 218 
Signaling, Massachusetts, USA) 219 
 220 
Analysis of cell-surface proteins by biotinylation 221 
The cell-surface proteins were labeled according manufacture protocol (Pierce™ Cell 222 
Surface Protein Isolation Kit (Prod#89881). Briefly, GH3 and MCF7 cell cultures were 223 
washed three times with ice-cold PBS buffer, pH 8, and then incubated with membrane 224 
impermeable sulfo-NHS-biotin at a final concentration of 0.3 mg/ml in PBS, pH 8, at 4 °C for 225 
20 min. After biotinylation, the cultures were washed three times with ice-cold PBS, and 226 
harvested with lysis buffer containing 1.25% Igepal CA-630, 1 mM EDTA, 2 mM PMSF, 10 227 
µg/ml leupeptin, and 10 µg/ml aprotinin (all inhibitors were from Sigma, St. Louis, MO). The 228 
cellular extracts were sonicated and incubated with avidin-agarose beads (Pierce, Rockford, 229 
IL) for 2 h at 4 °C. Then, the extracts were centrifuged at 500g for 10 min at 4 °C, the 230 
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supernatant (200 µl) was separated and the pellet was washed three times with 1 ml of lysis 231 
buffer. The proteins from the supernatant fractions were run in 7.5% acrylamide gel. Both 232 
pellet and supernatant fractions were analyzed by Western blot using specific antibodies. 233 
 234 
Western blot analysis 235 
Protein extracts (30 µg) were separated in a polyacrylamide gel (Sigma–Aldrich, St. 236 
Louis, MO, USA), transferred to a nitrocellulose membrane, and nonspecific binding blocked 237 
with PBS-5% non-fat dried milk at RT. The membranes were then rinsed and incubated 238 
overnight with anti-HER2 (1:1000), anti-pHER2 (1:350), anti-TBR1 (1:300), anti-TBR2 239 
(1:300), anti-Cyclin D1 (1:300, Santa Cruz Biotechnology, Dallas, TX, USA), anti-CDK4 240 
(1:400, Abcam, Cambridge, UK), anti-pSMAD2/3 (1:1000 Cell Signaling, Massachusetts, 241 
USA), anti-SMAD2/3 (1:1000, Cell Signaling, Massachusetts, USA), anti-TERK1 (1:500, 242 
Santa Cruz Biotechnology, Dallas, TX, USA), anti-pERK1/2 (1:1000, Cell Signaling, 243 
Massachusetts, USA) or anti-b-Actin (1:4000; Sigma Aldrich, St. Louis, MO, USA).  244 
The blots were incubated with HPRT-conjugated bovine anti-goat (1:2500; Santa 245 
Cruz Biotechnology, Dallas, TX, USA), goat anti-mouse (1:2500, Jackson ImmunoResearch, 246 
West Grove, PA, USA) or goat anti-rabbit secondary antibodies (1:5000, BioRad, Hercules, 247 
California, USA). The membranes were thoroughly rinsed in TBS 0.1% Tween 20, and the 248 
HPRT-coupled secondary antibody was revealed with enhanced chemiluminescence Western 249 
blotting detection reagents (GE Healthcare, Little Chalfont, UK). Emitted light was captured 250 
on Hyperfilm (GE Healthcare, Little Chalfont, UK). 251 
 252 
Confocal laser scanning microscopy 253 
Pituitary cells were fixed in 4% formaldehyde, permeabilized in 0.25% Triton X-100 254 
in PBS, blocked for 1 hour in PBS 3% BSA, and incubated with anti-HER2 (1:200) for 1 h. 255 
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Then, cells were incubated with Alexa Fluor 488 antirabbit antibody (1:2000; Invitrogen, 256 
Carlsbad, California, USA) for 1 h. Images were obtained using the inverted confocal laser 257 
scanning microscope FluoView FV 1200 (Olympus, Center Valley, PA). Serial z-axis 258 
sections were collected with an X60 objective and analysis of the confocal microscopy 259 
images was carried out using FV10-ASW 1.6 Viewer software. 260 
 261 
Immunogold electron microscopy (EM) 262 
The subcellular localization of the TGFB receptors in pituitaries from rats was 263 
examined by an ultrastructural immunocytochemical technique using protocols previously 264 
standardized in our laboratory (Petiti, et al. 2009). The grids were incubated with anti-TBR1 265 
(1:300) or anti-TBR2 (1:300) overnight at 4°C, and then with anti-mouse or antirabbit 266 
secondary antibodies conjugated to 15 nm (Electron Microscopy Science, Hatfield 267 
Pennsylvania, USA) colloidal gold particles (1:30). The following controls were performed: 268 
1) replacement of primary antiserum with PBS 1% BSA; and 2) replacement of primary 269 
antiserum with diluted pre-immune serum followed by the secondary antibody. Then, the 270 
sections were examined in a Zeiss LEO 906-E transmission EM (TEM) (Zeiss, Oberkochen, 271 
Germany) and photographed with a megaview III camera (Olympus, Center Valley, PA). 272 
 273 
Correlative Light and Electron Microscopy (CLEM)  274 
CLEM was carried out on ultrathin cryo-sections by applying the Tokuyasu technique 275 
as described by Oorschot (Oorschot, et al. 2014). Briefly, GH3 cells were fixed in 2% 276 
paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) and 0.2 % glutaraldehyde (Electron 277 
Microscopy Science, Hatfield, Pennsylvania, USA) for 2 h, embedded in 12 % gelatin, 278 
infiltrated with 2.3 M sucrose (Sigma-Aldrich, St. Louis, MO, USA) overnight at 48 °C, 279 
frozen in liquid nitrogen and sectioned at -120°C (100 nm cryosections) with a cryo-280 
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ultramicrotome RMC PowerTome-XL (RMC Boeckeler, Tucson Arizona, USA). Flat ribbons 281 
of 100nm thick cryo-sections, collected with 1.15 M sucrose and 1% methylcellulose (Sigma-282 
Aldrich, St. Louis, MO, USA), were transferred on formvar-coated 100-µm mesh hexagonal 283 
nickel grids (Electron Microscopy Science, Hatfield, Pennsylvania, USA).  284 
For immunolabeling, samples were incubated on 2% gelatin in PBS for 20 min at 285 
37°C, blocked, incubated with anti-HER2 1:50 ON at 4°C, rinsed and incubated with anti-286 
rabbit Alexa-Fluor 594 (Invitrogen, Carlsbad, California, USA) for 1h at 37°C in the 287 
presence of 40,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, St. Louis, MO, USA). 288 
For immunogold labelling, grids were incubated with gold conjugated protein-A 1:15 at 37 289 
°C for 1h.  290 
For fluorescence light microscopy (FLM), grids layered with a 200nm coat of 2% 291 
methylcellulose were mounted between a microscope slide and coverslip with 50% glycerol 292 
in water. For TEM, grids were unmounted, washed in Milli-Q water and incubated for 5 min 293 
in 0.4% uranyl acetate and 1.8% methylcellulose. Fluorescence images were obtained using a 294 
FluoView FV 1200 microscope and EM images using a Zeiss LEO 906-E TEM. The analysis 295 
was carried out with ImageJ software. 296 
 297 
Double-Immunohistochemistry on pituitary cryosections 298 
To assess co-expression of Ki67/PRL, Ki67/GH, Ki67/ACTH and Trastuzumab-299 
HER2/PRL, additional sets of pituitaries from different experimental conditions were used 300 
for confocal microscopy. Pituitary semi-thin cryo-sections were obtained by the Tokuyasu 301 
technique as described above. Then, the pituitary slices were incubated ON with anti-PRL 302 
(1/3000), anti-GH (1/3000), anti-ACTH (1/1000), anti-Ki67 (1/50) or Trastuzumab (1/1000) 303 
at 4ºC. These slices were washed and incubated with FITC anti-human, Alexa 594 anti-rabbit 304 
or Alexa 488 anti-mouse secondary antibodies (1:3000; Dako, Invitrogen) for 1 h, and with 305 
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DAPI for 10min. The images were then obtained using a FluoView FV 1200 microscope. The 306 
analysis of the images was carried out using ImageJ software. 307 
 308 
Computational structural analysis 309 
The crystal structures and amino acid sequences of the extracellular region of rat 310 
sHER2 (code:1n8y) and human sHER2 (code1: n8z) (Cho, et al. 2003) were downloaded 311 
from the Protein Data Bank (www.rcsb.org) and superposition of the structures was 312 
calculated with the program ProFit (http://www.bioinf.org.uk/software/profit/).  Sequence 313 
alignment was performed with ClustalX (Larkin, et al. 2007), molecular images were created 314 
with VMD (Humphrey, et al. 1996), and the effect of change of the amino acid sequence on 315 
binding affinity was calculated with MutaBind (Li, et al. 2016). 316 
 317 
Statistical analysis 318 
The experimental points represented the mean ± SEM of 3 replicates measured in 3 319 
independent cell cultures. A statistical analysis was carried out using the t-test or ANOVA 320 
followed by the Fisher test using the InfoStat program. Significance levels were chosen as P 321 
< 0.05. 322 
 323 
RESULTS 324 
Expression of HER2 and TBRs in human pituitary adenomas 325 
To investigate the protein expression of HER2 and TBRs in normal pituitaries (n=6) 326 
and in different types of human pituitary adenoma samples (table 1, n=20), we examined 327 
these receptors by immunohistochemistry (IHC, n=12) or western blot (WB, n=8) in non-328 
functioning and functioning tumors. As shown in table 2, HER2 expression was present in 329 
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three out of four prolactinomas with different percentages of positive cells (10%, 44% and 330 
27%); and also in one out of three and one out of four in GH-secreting and non-functioning 331 
tumors respectively, with a high percentage of HER2+ cells (79% and 98%) and strong 332 
staining (+++) observed, which was similar to the percentage present in the ACTH-secreting 333 
adenoma (80%). Ductal human breast carcinoma tissue samples were used as 334 
immunoreactive controls (Figure 1A). 335 
It has been previously reported that the phosphorylation status of HER2 protein 336 
provides more accurate information on the clinical outcome of patients undergoing 337 
trastuzumab treatment (Hudelist, et al. 2006). We analyzed the expression of pHER2 by IHC 338 
in seven pituitary adenomas including two PRL, GH-secreting and non-functioning ones, 339 
which were positive or negative for HER2, and also in an ACTH-secreting pituitary adenoma 340 
(table 2). The pHER2 was detected in the GH, ACTH-secreting and non-functioning pituitary 341 
adenomas that were highly positive for HER2, while the prolactinomas did not express 342 
pHER2. An interesting finding was the detection of pHER2 in the HER2 negative non-343 
functioning adenoma (table 2 and Figure 1A). 344 
With respect to the expression of the TGFB receptors, we observed a varied 345 
expression in the different pituitary tumors. The quantification of the different receptors in 346 
non-tumor pituitaries is showed in table 2. 347 
In parallel with the IHC analyzes, we determined the HER2 expression in eight other 348 
patients with pituitary adenomas (four GH secreting and four non-functioning adenomas) and 349 
5 non-tumor pituitaries using WB, revealing a marked expression in pituitary tumor samples 350 
compared to non-tumor pituitaries (Figure 1B). None of the pituitary tumor sample were 351 
observed to be positive to pHER2 (ptyr-1248 HER2) (Figure 1B). 352 
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 With respect to the TGFB receptors, we observed a reduced expression of TBR2 in 353 
pituitary tumors compared to non-tumor pituitaries (Figure 1B), while no differences were 354 
detected for TBR1. 355 
In addition, in order to investigate HER/ERK1/2 signaling, we determined the 356 
activation of ERK1/2 in human pituitary adenomas by WB. A significant increase in the 357 
phosphorylation of ERK1/2 was observed in the pituitary tumors analyzed compared to non-358 
tumor tissue (Figure 1B).  359 
Trastuzumab effect on rat pituitary tumors in vivo 360 
To evaluate in vivo effects of HER2 inhibition on pituitary tumor growth, we used 361 
experimental PRL pituitary tumors, which were treated with trastuzumab. First, we 362 
determined whether trastuzumab, as the primary antibody (Bussolati, et al. 2005; Glazyrin, et 363 
al. 2007), could bind the HER2 receptor in different human samples as well as in extracts 364 
from the rodent model (Estrogen-treated Fisher rat) and rat GH3 cells. As shown in figure 2, 365 
trastuzumab recognized the HER2 receptor in the human tumors and in different rat samples, 366 
as was confirmed by the presence of a band at 185 kDa, which corresponded to the molecular 367 
weight of HER2 from total extract samples (Figure 2A) and purified cell surface proteins 368 
samples (Figure 2B). With the aim of further strengthening these results, we investigated the 369 
trastuzumab/HER2 interactions in rat GH3 cells and in human breast tumor sample with 370 
HER2 amplification by immunoprecipitation assays. The HER2 receptor was precipitated in 371 
an immune complex with trastuzumab as primary antibody, and then immunoblotting with 372 
the anti-HER2 antibody was performed (Figure 2C). As was expected, Trastuzumab 373 
interacted with human HER2 and, also to a lesser intensity with rat HER2, indicating a 374 
possible trastuzumab/rat HER2 interaction in GH3 cells. In addition, comparing human and 375 
rat HER2 sequences by computational analysis, three different amino acids (P571S, P572S 376 
Page 15 of 45
and F573S) have been identified in the binding interface. Out of the three amino acid 377 
differences present, only P572S was predicted to be deleterious, but with a low confidence 378 
(Supplementary Table 1 and Figure 1). The other two alterations were predicted to reduce the 379 
binding affinity, but not to be deleterious. These results show a highly conserved binding 380 
interface with three points of amino acid differences, which could predict a reduced affinity 381 
of Trastuzumab by rat HER2 compared to human sHER2, in line with the 382 
immunoprecipitation assays. 383 
In addition, we performed IHC using trastuzumab as the primary antibody for HER2 384 
detection on cryosections from rat pituitary tumor, and observed immunofluorescence in the 385 
plasma membrane and cytoplasm in rat pituitary tumor cells. Moreover, we realized double-386 
immunofluorescence staining for HER2 (using trastuzumab) and PRL, which revealed PRL 387 
positive cells with HER2 labelling delineating the plasma membrane, as can be observed in 388 
the figure 2D. 389 
 Next, we analyzed HER2 and TBR expression in experimental pituitary tumors 390 
exposed to the HER2 inhibitor by IHC with the HER2 quantification indicating an increase of 391 
expression in the E and E+T groups with respect to the non-estrogen(C) and control–392 
trastazumab (T) groups. In addition, the quantification of both TGFB receptors (TBR1 and 393 
TBR2), showed a decrease in E and E+T compared to the C and T groups (Figure 2E).  394 
To investigate further the results obtained by conventional IHC, we examined the 395 
subcellular localization of both TBRs in experimental pituitary tumors treated with 396 
trastuzumab by means of TEM immunogold. In the pituitary tumors without trastuzumab 397 
administration, the subcellular distribution of TBR1 and TBR2 was similar, as identified by 398 
gold particles in the plasma membrane and cytoplasm. In some cells, the cytoplasmic 399 
presence of both receptors was associated with an endoplasmic reticulum (Figure 2F). 400 
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However, the administration of the HER2 inhibitor did not induce any changes in the 401 
subcellular localization of either TGFR receptor. 402 
Having demonstrated that the rat pituitary tumors expressed HER2, we now tested the 403 
effect of HER2 blockade on pituitary weight and cell proliferation, with cells which were 404 
immunoreactive to the mitogenic marker Ki67 in sections from three different levels of 405 
pituitary glands of each experimental group being quantified as shown in Figure 3A-B. The 406 
pituitary tumor proliferation decreased by about 50% (average percentages C: 1.5%; T: 1.3%; 407 
E: 18.75%; and E+T: 8.3%) after treatment with trastuzumab for two weeks. In addition, we 408 
performed double-immunostaining of PRL, GH or ACTH hormones with Ki67 in the 409 
Estrogen-treated rat group. As expected, the majority of cells identified in this experimental 410 
group were PRL+, with some of these being co-labelled with Ki67 and a few GH/Ki67 411 
positive cells being detected. However, the ACTH cells were negative to Ki67, as shown in 412 
the Figure 3C. 413 
In order to elucidate whether the cell proliferation decrease observed after 414 
trastuzumab treatment could be associated with an increase in apoptosis, we used the TUNEL 415 
assay as this is useful for examining DNA fragmentation in situ, and apoptosis of pituitary 416 
cells was evaluated over histological samples of each experimental group. As shown in the 417 
Figure 3D, no changes were observed in the number of TUNEL positive cells in the different 418 
experimental groups.  419 
Trastuzumab effect on the protein expression of cell-cycle regulators 420 
The activation of the HER2 receptor promotes cell proliferation through the 421 
stimulation of proteins involved in the control of the cell cycle progression. After observing 422 
that the inhibition of HER2 decreased the proliferation of pituitary tumor cells in vivo, we 423 
investigated whether the trastuzumab effects on the expression of ERK1/2, Cyclin D1 and 424 
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CDK4. As shown in Figure 3E-G, the treatment with trastuzumab significantly reduced the 425 
expression of all the mitogenic proteins analyzed, compared to the pituitary tumors from rats 426 
without treatment with the HER2 inhibitor, in agreement with the blockade observed in the 427 
cell proliferation in Figure 2.  428 
Trastuzumab effect on TGFB1 signaling in vitro 429 
Having analyzed the key role of HER2 on the pituitary tumor cell proliferation, we 430 
investigated whether the trastuzumab treatment could modulate the anti-mitogenic effect of 431 
TGFB1. To carry this out, we used GH3 lactosomatotroph pituitary tumor cells and first 432 
determined the expression of HER2 by confocal microscopy (Figure 4A) and CLEM (Figure 433 
4B), which allowed the simultaneous observation of a given subcellular structure. As shown 434 
in figure 4A and B, the receptor was localized at the plasma membrane, similar to the 435 
location found in colon cancer CaCO2 cells used as a positive control.  436 
To investigate whether blocking HER2 regulated TGFB1-induced cell proliferation 437 
inhibition, we quantified the levels of Ki67 by flow cytometry in GH3 cells exposed to 438 
TGFB1 in the presence of trastuzumab.  It was observed that the treatment with TGFB1 or 439 
trastuzumab significantly decreased the cell proliferation, an effect that was potentiated when 440 
the GH3 cells were co-incubated with TGFB1 and trastuzumab (Figure 4B). In parallel we 441 
performed new assays using the bromodeoxyuridine (BrdU) technique, which is commonly 442 
used to measure cell proliferation. Similar results were obtained, thus confirming those 443 
adquired by Ki67 measurements (Figure 4C).  444 
After demonstrating the inhibition of cell proliferation by co-incubation with 445 
trastuzumab and TGFB1, we decided to study whether this effect was associated with 446 
activation of SMAD2/3. A significant increase in p-Smad2/3 expression occurred when GH3 447 
cells were incubated with trastuzumab in the presence of TGFB1 (Figure 4D), suggesting that 448 
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activation of the canonical signal TGFB1/SMAD2/3 was inhibited by the signaling pathways 449 
activated by HER2.  450 
To evaluate the effect of trastuzumab and TGFB1 on ERK1/2 activation, the GH3 451 
cells were treated with the HER2 inhibitor for 30 min in the presence or absence of TGFB1, 452 
and their phosphorylated states were determined by WB. As shown in Figure 4E, the analysis 453 
of pERK1/2 did not reveal any changes in the ERK1/2 pathway activation after TGFB1 454 
stimulation. However, treatment with trastuzumab co-incubated with TGFB1 for 30 min 455 
induced a significant decrease in the phosphorylation of ERK1/2. 456 
In order to try to obtain more evidence of crosstalk between HER2/ERK1/2 and 457 
TBR/SMAD2/3, we analyzed the interaction of SMAD2/3 with ERK1/2 using 458 
immunoprecipitation studies on GH3 cells treated with trastuzumab in the presence of 459 
TGFβ1. The interaction of p-SMAD2/3-p-ERK1/2 decreased when the GH3 cells were 460 
incubated with trastuzumab in the presence of TGFβ1, compared with the treatment with 461 
TGFβ1 alone, effects that may be associated with the reduction in p-ERK1/2 and the increase 462 
of p-Smad2/3 observed in Figure 4F. 463 
A possible mechanism to regulate SMAD2/3 phosphorylation is by controlling the 464 
pool of Smad2/3 available for TGFβ signaling. The high phosphorylation of SMAD2/3 in the 465 
presence of trastuzumab (Figure 4D) and the interaction between SMAD2/3 with ERK1/2 466 
(Figure 4F) led us to hypothesize that these MAPK altered the SMAD2/3 phosphorylation 467 
induced by TβRI. Thus, we tested the interaction between TBR1 and SMAD2/3 by 468 
immunoprecipitation assays in GH3 treated with trastuzumab in the presence of TGFB1, an 469 
increase in TBR1-SMAD2/3 association was observed when the cells were co-incubated with 470 
the inhibitor of the HER2/ERK1/2 pathway and TGFB1. 471 
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The activation of SMAD2/3 can be regulated by controlling the pool of Smad2/3 472 
available for TGFB signaling. Thus, we studied whether blocking HER2 would alter the 473 
interaction of SMAD2/3 with TBR1 by using immunoprecipitation in the GH3 cells treated 474 
with trastuzumab or TGFB1. As shown in Figure 4F, the TGFB1 or HER2 inhibitor 475 
significantly increased interaction between SMAD2/3 and TBR1, effects that were 476 
potentiated in GH3 cells incubated with TGFB1 in the presence of trastuzumab. These results 477 
suggest that the HER2/ERK1/2 pathway inhibited SMAD2/3 phosphorylation by interfering 478 
with its association with the TGFB receptor.    479 
 480 
DISCUSSION 481 
In the present study, we demonstrated that inhibition of the HER2 receptor by 482 
trastuzumab decreased cell proliferation of pituitary tumor cells through blocking the ERK1/2 483 
pathways and facilitating the activation of antimitogenic TGFB/SMADs signaling.  484 
There are a wide variety of treatment options available to manage pituitary adenomas, 485 
such as pharmacotherapy with dopamine, as well as, somatostatin analogs, surgery, 486 
radiotherapy and chemotherapy. However, aggressive pituitary adenomas are notoriously 487 
difficult to manage due to their size, invasiveness, speed of growth and high frequency of 488 
recurrence (Buchfelder 2009). There is no clear definition of aggressive adenomas, but such 489 
tumors are generally considered (from the clinical point of view) to be those corresponding to 490 
a massive invasion of surrounding tissue, with features of rapid growth, large size, a tendency 491 
to recur rapidly, resistance to conventional treatments (including radiotherapy), and in some 492 
patients, a fatal outcome (Buchfelder 2009; Lloyd 2004). Specific biomarkers have not yet 493 
been identified that can distinguish between clinically aggressive and non-aggressive 494 
pituitary adenomas, although the antigen Ki67 proliferation index might be of use. The study 495 
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of aggressiveness in pituitary tumors is of crucial importance for improving the management 496 
of patients by enhancing prognostic predictions and the effectiveness of treatments. In this 497 
sense, it is clear the need for the development of an alternative strategy for recurrent invasive 498 
adenomas or those that are resistant to conventional therapies. 499 
We have demonstrated here the presence of HER2 in human non-functioning and in 500 
PRL, GH and ACTH secreting pituitary tumors. HER2 expression was previously found to be 501 
in 31% of all pituitary tumors, 43% of non-functioning ones and 24% of functioning 502 
adenomas (Cooper, et al. 2011). In different studies, HER2 expression has been confirmed in 503 
24% of GH-secreting, 26% of PRL-secreting, and 32% of GH/PRL adenomas, as well as in 504 
3% of the ACTH-secreting adenomas tested (Botelho, et al. 2006; Chaidarun, et al. 1994; 505 
Ezzat et al. 1997; Nose-Alberti et al. 1998; Vlotides et al. 2009). The higher HER2 506 
expression and proliferation index recorded in invasive adenomas compared to non-invasive 507 
ones suggests a worse prognosis in adenohypophyseal neoplasia (Nose-Alberti et al. 1998), 508 
making this receptor an attractive therapeutic target as an alternative medical therapy for 509 
pituitary tumors. The presence of intact HER2 signaling has been reported in tumors from 510 
breast cancer patients who were found to be HER2 negative by IHC. This subgroup of 511 
patients was excluded from trastuzumab treatment, although these patients may have 512 
responded to the drug (Wulfkuhle, et al. 2012). On analyzing the activation of HER2, we 513 
detected pHER2 expression in pituitary adenomas positive for HER2, interestingly in a HER2 514 
negative non-functioning adenoma by IHC. Nevertheless, the pHER2 expression could not be 515 
observed by WB, probably due to the differences in the sample processing that enables a 516 
better exposition of the antigen in IHC. The immuno detection of pHER2  could be clinically 517 
relevant, as it has been reported that some breast cancer patients with negative HER2 tumors 518 
present have benefited from trastuzumab (Paik, et al. 2008). 519 
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Considering that the HER2 effect and signaling are mediated by the MEK/ERK1/2 520 
cascade, we determined the activation of ERK1/2 in human pituitary tumors, with an increase 521 
in the phosphorylation of ERK1/2 in the pituitary tumors being observed compared to non-522 
tumor tissues. These results are in agreement with a previous report that demonstrated a rise 523 
in phosphorylation, and hence, activation of MEK1/2 and ERK1/2 in all pituitary adenoma 524 
subtypes compared to normal pituitaries (Dworakowska et al. 2009). In rat prolactinoma 525 
tumor cells, treatment with the EGFR inhibitor gefitinib suppressed proliferation and ERK1/2 526 
phosphorylation, thereby demonstrating the involvement of EGFR/ERK signaling in pituitary 527 
tumor growth (Vlotides, et al. 2008). To obtain a deeper understanding of the role of the 528 
HER2/ERK pathway in pituitary tumor growth, it would be interesting to study possible 529 
crosstalk with TGFB signaling, which may help to improve the therapeutic strategy against 530 
HER2. 531 
TGFB signaling in the development of pituitary tumors is still not fully understood 532 
and the subject of much controversy.  In normal epithelial cells, TGFB1 acts as a potent 533 
tumor suppressor and prevents incipient tumors from progression to malignancy. However, 534 
due to the subsequent inactivation of TGFB signaling or key target genes, tumor cells lose 535 
their TGFB1 tumor-suppressive responses (Massague 2008). Considering that tumor cells can 536 
evade the suppressive effects of TGFB through inactivation of core components of the 537 
pathway (such as TGFB receptors), we examined the protein expression of TGFB receptors 538 
in normal and tumoral human pituitaries, with reduced TBR2 levels being observed in the 539 
tumor tissues compared to non-tumoral pituitaries. These results are in agreement with 540 
previous reports that described immunoreactivity for TBR2 expression in 26 out of 48 cases 541 
of human pituitary adenomas (Fujiwara, et al. 1995) and a down-regulation of the 542 
TGFB/SMAD signaling cascade in dopamine-resistant prolactinomas compared to normal 543 
human anterior pituitaries (Li, et al. 2015). Our results on TBRs obtained from human 544 
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samples suggest that TGFB signaling may be restrained in pituitary adenomas and might be 545 
correlated with tumor growth. Consequently, recovering the capability of TGFB signaling to 546 
suppress tumor development could be a promising therapeutic strategy for pituitary tumors. 547 
Pituitary tumors are often unresponsive to therapy, and even when an initial response 548 
is achieved, their recurrence is common. Bearing in mind the presence of HER2 in human 549 
pituitary tumors, we investigated the effect of specific HER2 inhibition with trastuzumab on 550 
pituitary tumor cell growth by employing two experimental approaches; an in vivo pituitary 551 
tumor model using Fisher 344 rats and in vitro experiments performed with rat GH3 552 
lactosomatotroph pituitary tumor cell line. In this study, it was demonstrated that the human-553 
specific HER2 monoclonal antibody (trastuzumab) recognized rat-derived HER2 in both the 554 
rodent model and GH3 cells. The analysis of cell-surface proteins by biotinylation and the 555 
theorical model of trastuzumab/HER2 interaction showed differences between human and rat 556 
binding. The experimental PRL pituitary tumor presented a significant HER2 expression, in 557 
contrast to decreased TBR1 and TBR2 receptors. The HER2 inhibitor treatment decreased the 558 
pituitary tumor weight, cell proliferation, without inducing apoptosis, and the levels of 559 
mitogenic MAPK-ERK1/2 signaling. In addition, trastuzumab administration for two weeks 560 
in estrogen-treated rats inhibited the expression of CDK4 and cyclin D1, key regulators of the 561 
cell cycle progression from G1 to the S phase (Sherr and Roberts 1995). The trastuzumab 562 
treatment in non-estrogen treated rats did not change any of the parameters analyzed with 563 
respect to intact animals, suggesting that the trastuzumab effect takes place when there is a 564 
previous PRL pituitary tumor, which was associated with the high HER2 expression recorded 565 
in the E group.  566 
It has been reported in transgenic mice models that CDK4 is required for both the 567 
physiological and tumorigenic control of cell cycle progression in the pituitary (Gillam, et al. 568 
2015). During the G1 phase, CDK4 is activated by cyclin D1 (Sherr and Roberts 1995), 569 
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which has been previously observed to be overexpressed in 22 of 45 human pituitary tumors 570 
analyzed (Simpson, et al. 2001). It has been reported that lactotroph cells of CDK4-deficient 571 
mice did not proliferate in response to estrogen administration (Moons, et al. 2002). In the 572 
present study, the noticeable increase of CDK4 expression observed in the E group suggests 573 
the contribution of both proteins (cyclin D1 and CDK4) in the regulation of tumor pituitary 574 
proliferation. Thus, these results provide evidence that the inhibition effect of trastuzumab on 575 
pituitary tumor growth in vivo can be mediated by blocking the G1/S-specific ERK1/2/cyclin 576 
D1/CDK4 pathway.  577 
Although the blocking of HER2, an inhibitory effect on pituitary tumor growth has 578 
been previously described by using lapatinib (a dual tyrosine kinase inhibitor of both EGF 579 
receptors HER1 and HER2 (Fukuoka et al. 2011), this is the first study testing the specific 580 
HER2 inhibitor trastuzumab on pituitary tumor cells, which is a widely promising agent for 581 
molecular targeting therapy against breast cancer and more recently tested in patients with 582 
HER2-positive colorectal cancer (Carter, et al. 1992; Ross, et al. 2009; Sartore-Bianchi, et al. 583 
2016). Considering the relevance of EGF receptors in pituitary tumor progression, the EGFR 584 
antagonist lapatinib in conjunction with a dopamine agonist was evaluated in patients with 585 
dopamine analog-resistant prolactinomas and demonstrated a beneficial effect of the EGFR 586 
inhibitor in the clinical outcome, including reduced prolactin levels and tumor shrinkage 587 
(Cooper, et al. 2014). In a related study performed on patients with advanced breast cancer, it 588 
was demonstrated that the lower pathological complete response rates in the lapatinib treated 589 
group might be explained by a reduced capability of the tyrosine-kinase-inhibitor to block the 590 
HER2 pathway compared with the trastuzumab antibody (Untch, et al. 2012). These reports, 591 
in addition to our results, suggest that the study of the specific inhibition of HER2 by 592 
trastuzumab in pituitary tumors should be expanded, in view of the attractive therapeutic 593 
target HER2 in pituitary adenomas. It would be relevant to determine the trastuzumab/HER2 594 
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binding in human pituitary cells, which may predict the efficacy of the treatment in pre-595 
clinical human studies. In the present study, considering the presence of HER2 positive cells 596 
in three out of four human prolactinomas, and also in the experimental pituitary tumor used, 597 
the principal target for trastuzumab treatment could be PRL producing tumors. However, 598 
taking into account the high percentage (79%) and strong staining (+++) of HER2 expression 599 
in one out of three GH-producing tumors, and also the presence of Ki67/GH positive cells in 600 
the estrogen-treated rat group, we suggest that trastuzumab might have an effect on GH 601 
secreting tumors. Future work should expand the number of cases using appropriate 602 
experimental pituitary tumor models.  603 
Having demonstrated the anti-proliferative effect of trastuzumab in pituitary tumor 604 
growth, we investigated possible cross-talk with TGFB signaling, which has not yet been 605 
studied in pituitary tumors. Trastuzumab treatment in the presence of TGFB1 decreased GH3 606 
cell proliferation significantly, an effect accompanied by a reduction in ERK1/2 607 
phosphorylation, an increase in SMAD2/3 activation suggesting a negative role of the 608 
HER2/ERK1/2 pathway on the activation of SMAD2/3 in pituitary tumor cells. Although 609 
SMADs are activated by TβRI-mediated phosphorylation, their activity and stability are 610 
further regulated by downstream kinases of other signaling pathways (Matsuzaki 2011). In a 611 
previous report we demonstrated that the activation of ERK1/2 by EGF blocked SMAD2/3 612 
phosphorylation in pituitary tumor cells, and we also described a physical interaction between 613 
SMAD2/3 and ERK1/2, which  interfered with the association between SMAD2/3 and TBR1 614 
(Petiti et al. 2015). Here, we tested the interaction of SMAD2/3 with ERK1/2 and TBR1 by 615 
immunoprecipitation assays in rat GH3 cells treated with trastuzumab in the presence of 616 
TGFB1, and observed a decrease in SMAD2/3-ERK1/2 and an increase in SMAD2/3-TBR1 617 
associations. These results suggest that the reduction of pERK1/2 in cells treated with 618 
trastuzumab in the presence of TGFB1 could be associated with a decrease in SMAD2/3-619 
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ERK1/2 interaction, which might allow the SMAD2/3 pool to become available for activation 620 
by TBRI and consequently decrease the cell proliferation. Thus, the anti-proliferative effect 621 
of trastuzumab in pituitary tumor cells may be mediated by a blockade of the HER2/ERK1/2 622 
pathway and a consequent stimulation of the anti-mitogenic TGFB/TBR1/SMAD2/3 cascade.  623 
In conclusion, in the present study, using in vivo and in vitro models, we 624 
demonstrated that blocking HER2 by trastuzumab inhibited pituitary tumor growth and 625 
modulated HER2/ERK1/2 signaling and consequently the anti-mitogenic TGFB/TBR/SMAD 626 
signaling (Figure 5). Furthermore, the high expression of HER2 and ERK1/2 in contrast with 627 
the low levels of TBR2 detected in hu man pituitary adenomas may have been responsible, at 628 
least in part, for the limited antiproliferative response to TGFB1detected in pituitary tumor 629 
cells (Sarkar, et al. 1998). This imbalance between proliferative and anti-proliferative signals 630 
in pituitary tumor cells has also been previously described in breast cancer, with HER2-631 
induced tumorigenesis in an in vivo model resulting in the loss of the TGFB signaling 632 
pathway and a lack of SMAD2 activation, accompanied by a reduction of TBR1 expression 633 
(Landis, et al. 2005).  634 
The loss of tissue homeostasis by alteration in HER2 and TBRs signaling, the 635 
frequent resistance to therapy and the early recurrence of aggressive pituitary tumors led us to 636 
investigate new pharmacological strategies. The inhibition of HER2/ERK1/2 pathway is 637 
attractive, but undoubtedly new studies are now needed that consider a more integrated vision 638 
that involves intricate relations with other signaling pathways. 639 
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 1 
LEGENDS 2 
Figure 1:  3 
HER2 and TBRs expression in human pituitary adenomas. (A) Representative micrographs of 4 
the immunohistochemical analysis of HER2, pHER2, TBR1 and TBR2 expression in human 5 
non-tumor and pituitary tumor samples. HER2 positive (M+) and negative (M-) breast tumor 6 
samples were used as controls. Scale bar: 20µm. Representative western blot images of (B) 7 
HER2 and pHER2, (C) TBR1, TBR2, pERK1/2 and T-ERK1/2 expression in non-tumor 8 
pituitaries and pituitary adenomas. PRL: PRL-secreting, GH: GH-secreting, ACTH: ACTH-9 
secreting and NF: non-secreting pituitary tumors. 10 
Figure 2:  11 
HER2 and TBR expression in rat pituitary tumors. (A) Western blot detection of HER2 in 12 
total extracts from rat pituitary tumors (F1 and F2) and rat GH3 pituitary tumor cells using 13 
trastuzumab as the primary antibody. Human HER2+ (M+) breast tumor, CaCo2 and MCF7 14 
lysates were used as positive controls an human HER2- (M-) breast tumor as negative 15 
control. (B) Analysis of cell-surface proteins by biotinylation. Trastuzumab recognized the 16 
HER2 receptor in GH3 and MCF7 pellet samples, as confirmed by the presence of a band at 17 
185 kDa, corresponding to the molecular weight of HER2, without any expression in the 18 
supernatant fractions as expected. The same result was observed using anti-HER2 as primary 19 
antibody. The expression of NFkB was used as negative control of cell surface proteins, with 20 
its presence being observed only in the supernatant fractions, indicating the purity of the 21 
isolation. (C) Trastuzumab/HER2 interactions in rat GH3 cells and in human breast tumor 22 
sample with HER2 amplification by immunoprecipitation assays. The HER2 receptor was 23 
precipitated in an immune complex with trastuzumab as primary antibody, and then anti-24 
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HER2 antibody was used for the immunoblotting. (D) Immunofluorescence staining for 25 
HER2 and PRL on cryo-sections of a rat pituitary tumor. On the left panel, white arrowheads 26 
indicate HER2 expression at the plasma membrane, while double positive (HER2-PRL) cells 27 
are shown on the right panel. Scale bar: 20um. (E) Representative micrographs and 28 
quantification of immunohistochemistry staining for HER2, TBR1 and TBR2 in the 29 
following groups: control [C], trastuzumab [T], estrogen-induced rat pituitary tumors [E] and 30 
estrogen-induced rat pituitary tumors treated with trastuzumab (6 mg/kg) for the last 15 days 31 
of estrogen exposure [E+T]. Scale bar: 20 µm. *** p<0.001 E vs. C. (F) Immuno-gold 32 
labelling for TBR1 and TBR2 on E and E+T groups. Arrows show the localization of TBR1 33 
and TBR2 at the plasma membrane and the endoplasmic reticulum (ER).  34 
 Figure 3:   35 
Effect of trastuzumab treatment on rat experimental pituitary tumors. (A) Pituitary gland 36 
weight (mg) and the corresponding representative photographs from C, T, E and E+T groups. 37 
*p<0.05 E vs. C or T and ^p<0.05 E+T vs. E. (B) Representative micrographs and 38 
quantitative analysis of immunohistochemistry staining for Ki67 as a proliferation marker. 39 
Scale bar 20um. *p<0.05 E vs. C or T and ^p<0.05 E+T vs. E. (C) Double-40 
immunofluorescence staining for Ki67 (green) and PRL, GH or ACTH (red) in pituitary 41 
ultrathin cryo-sections from the E group. Scale bar 10um. Double-positive cells are indicated 42 
with an asterisk (*). (D) TUNEL assay from C, T, E and E+T groups. Arrowheads indicate 43 
apoptotic cells. Negative control [C-]: pituitary gland section without corresponding primary 44 
antibody. Positive control [C+]: pituitary gland section treated with DNAase I. Scale bar 45 
20um. Western blot analysis of proliferation and cell cycle-regulator proteins. Representative 46 
panels and densitometric analysis of (E) pERK1/2-ERK1/2, (F) Cyclin D1, (G) CDK4 protein 47 
expression. * p<0.05 E vs. C or T and ^ p<0.05 E+T vs. E. 48 
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 49 
Figure 4: 50 
 Effect of trastuzumab on the antiproliferative response to TGFB1. (A) Representative images 51 
of immunofluorescence labelling for HER2 in GH3 and CaCO2 (positive control) cell lines. 52 
White arrowheads indicate the expression of the receptor at the plasma membrane. Scale bar 53 
10um. Correlative Light and Electron Microscopy (CLEM): [1] Immunofluorescence images 54 
for HER2 detection in ultrathin cryo-sections of GH3 cells (scale bar 10um). [2] CLEM 55 
overlay of TEM and the corresponding FLM image. [3] TEM images for the whole section 56 
and, at higher magnification, the immuno-gold labelling for selected regions (a, b) shown by 57 
white boxes. Gold particles are indicated by black arrows. Cell proliferation analysis in GH3 58 
cells, which were treated with TGFB1 (4 ng/ml), Trastuzumab (Trast, 100 mM) or the 59 
combination of both factors for 24 h. (B) Representative flow cytometry histograms and 60 
quantitative analysis of the proliferation-associated protein Ki67. (C) Representative 61 
micrographs and quantification of BrdU uptake. *p<0.05 TGFB1 or Trast vs. C, and ^p<0.05 62 
TGFB1+Trast vs. TGFB1 or Trast. TGFB1 and MAPK-ERK1/2 signaling pathway analysis. 63 
Western blot panels and relative quantification of (D) pSMAD2/3-TSMAD2/3 and (E) 64 
pERK1/2-ERK1/2 expression from GH3 cell cultures treated with TGFB1, Trastuzumab or 65 
their combination for 30 min. (F) Immunoprecipitation (IP) of pSMAD2/3 and pERK1/2 and 66 
TBRI immunodetection in total cell extracts of GH3 cell cultures, untreated and treated for 30 67 
min with Trastuzumab, TGFB1 or their combination. Input: TBRI or pERK1/2 or pSMAD2/3 68 
antibody recognized the antigen in the total cell culture lysate.  69 
Figure 5.  70 
Model for the cross talk of HER2/ERK1/2 with TGFβ1/SMAD pathways in pituitary GH3 71 
cells. Blocking HER2 by trastuzumab inhibits pituitary tumor growth and modulates 72 
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HER2/ERK1/2 signaling, and consequently the anti-mitogenic TGFB/TBR/SMAD signaling. 73 
The HER2/ERK1/2 pathway impinges on the TGFβ1/SMAD2/3 signaling, thereby 74 
modulating SMAD2/3 phosphorylation. The association of SMAD2/3-ERK1/2 inhibits the 75 
TβRI induced- SMAD2/3 activation, thus counteracting the antimitogenic effect of TGFβ1.  76 
 77 
Supplementary Figure 1. (A) Sequence alignment of the C-terminal of rat and human sHER2. 78 
The residues in the binding interface with Trastuzumab are marked with hyphens. An amino 79 
acid was defined as interfacial if its Cα was within 9A of any Cα of Trastuzumab. (B) 80 
Superposition of rat (pdb: 1n8y, blue) and human (pdb:1n8z, green) structures of sHER2. The 81 
Trastuzumab molecule is shown on the surface in red and grey. The Cα atoms of sHER2 at 82 
the binding interface are shown as spheres. 83 
 84 
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TABLE 1: Clinicopathologic and immunohistochemical characteristics of human pituitary adenomas 
Case Gender/age Clinicopathologic 
classification 
IHC Ki67 % 
1 F/20 Functioning PRL 1 
2 F/38 Functioning PRL 1 
3 F/31 Functioning PRL 1 
4 F/26 Functioning PRL 1 
5 F/58 Functioning GH 3 
6 F/37 Functioning GH 2 
7 F/57 Functioning GH 2 
8 F/27 Functioning GH 1 
9 M/31 Functioning GH 1 
10 F/64 Functioning GH N.D. 
11 F/32 Functioning ACTH 5 
12 F/62 Functioning ACTH 2 
13 M/63 Non-functioning Negative 5 
14 M/44 Non-functioning Negative 1 
15 F/45 Non-functioning Negative 3 
16 M/58 Non-functioning Negative 3 
17 F/68 Non-functioning Negative 2 
18 M/56 Non-functioning Negative 5 
19 F/62 Non-functioning Negative 1 
20 M/50 Non-functioning Negative 1 
M: male, F: female, GH: Growth hormone; ACTH: Adenocorticotroph hormone.; PRL: Prolactin; N/D: no data 
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TABLE 2: Immunohistochemical characteristics of human pituitary samples 
Case Gender/age Clinicopathologic 
classification 
IHC Ki67 % HER2% pHER2 TBRI% TBRII% 
1 F/20 Functioning PRL 1 10++ 0 100 100 
2 F/38 Functioning PRL 1 44+ N/D 100 94 
3 F/31 Functioning PRL 1 27+ N/D 100 0 
4 F/26 Functioning PRL 1 0 0 100 1 
5 F/58 Functioning GH 3 79+++ 36.1 51 100 
6 F/37 Functioning GH 2 0 0 52 40 
7 F/57 Functioning GH 2 0 N/D 94 0 
8 F/32 Functioning ACTH 5 80+++ 59.1 40 72.8 
9 M/63 Non-functioning Negative 5 0 10.5 16 N/D 
10 M/44 Non-functioning Negative 1 98+++ 49.5 26 100 
11 F/45 Non-functioning Negative 3 0 N/D 11 0 
12 M/58 Non-functioning Negative 3 0 N/D 0 80 
13 F/54 Non-tumor tissue N/A N/A 0 N/D 100 80 
14 M/35 Non-tumor tissue N/A N/A 0 N/D 28 80 
15 M/57 Non-tumor tissue N/A N/A 5+ 0 60 90 
M: male, F: female, GH: Growth hormone; ACTH: Adenocorticotroph hormone; PRL: Prolactin. N/D: no data.  
Staining score: +=low, ++=moderate, +++= strong. 
 




Figure 1: HER2 and TBRs expression in human pituitary adenomas. (A) Representative micrographs of the 
immunohistochemical analysis of HER2, pHER2, TBR1 and TBR2 expression in human non-tumor and 
pituitary tumor samples. HER2 positive (M+) and negative (M-) breast tumor samples were used as 
controls. Scale bar: 20µm. Representative western blot images of (B) HER2 and pHER2, (C) TBR1, TBR2, 
pERK1/2 and T-ERK1/2 expression in non-tumor pituitaries and pituitary adenomas. PRL: PRL-secreting, 
GH: GH-secreting, ACTH: ACTH-secreting and NF: non- secreting pituitary tumors.   
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Figure 2:  
HER2 and TBR expression in rat pituitary tumors. (A) Western blot detection of HER2 in total extracts from 
rat pituitary tumors (F1 and F2) and rat GH3 pituitary tumor cells using trastuzumab as the primary 
antibody. Human HER2+ (M+) breast tumor, CaCo2 and MCF7 lysates were used as positive controls an 
human HER2- (M-) breast tumor as negative control. (B) Analysis of cell-surface proteins by biotinylation. 
Trastuzumab recognized the HER2 receptor in GH3 and MCF7 pellet samples, as confirmed by the presence 
of a band at 185 kDa, corresponding to the molecular weight of HER2, without any expression in the 
supernatant fractions as expected. The same result was observed using anti-HER2 as primary antibody. The 
expression of NFkB was used as negative control of cell surface proteins, with its presence being observed 
only in the supernatant fractions, indicating the purity of the isolation. (C) Trastuzumab/HER2 interactions in 
rat GH3 cells and in human breast tumor sample with HER2 amplification by immunoprecipitation assays. 
The HER2 receptor was precipitated in an immune complex with trastuzumab as primary antibody, and then 
anti-HER2 antibody was used for the immunoblotting. (D) Immunofluorescence staining for HER2 and PRL 
on cryo-sections of a rat pituitary tumor. On the left panel, white arrowheads indicate HER2 expression at 
the plasma membrane, while double positive (HER2-PRL) cells are shown on the right panel. Scale bar: 
20um. (E) Representative micrographs and quantification of immunohistochemistry staining for HER2, TBR1 
and TBR2 in the following groups: control [C], trastuzumab [T], estrogen-induced rat pituitary tumors [E] 
and estrogen-induced rat pituitary tumors treated with trastuzumab (6 mg/kg) for the last 15 days of 
estrogen exposure [E+T]. Scale bar: 20 µm. *** p<0.001 E vs. C. (F) Immuno-gold labelling for TBR1 and 
TBR2 on E and E+T groups. Arrows show the localization of TBR1 and TBR2 at the plasma membrane and 
the endoplasmic reticulum (ER).  
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Figure 3:    
Effect of trastuzumab treatment on rat experimental pituitary tumors. (A) Pituitary gland weight (mg) and 
the corresponding representative photographs from C, T, E and E+T groups. *p<0.05 E vs. C or T and 
^p<0.05 E+T vs. E. (B) Representative micrographs and quantitative analysis of immunohistochemistry 
staining for Ki67 as a proliferation marker. Scale bar 20um. *p<0.05 E vs. C or T and ^p<0.05 E+T vs. E. 
(C) Double-immunofluorescence staining for Ki67 (green) and PRL, GH or ACTH (red) in pituitary ultrathin 
cryo-sections from the E group. Scale bar 10um. Double-positive cells are indicated with an asterisk (*). (D) 
TUNEL assay from C, T, E and E+T groups. Arrowheads indicate apoptotic cells. Negative control [C-]: 
pituitary gland section without corresponding primary antibody. Positive control [C+]: pituitary gland section 
treated with DNAase I. Scale bar 20um. Western blot analysis of proliferation and cell cycle-regulator 
proteins. Representative panels and densitometric analysis of (E) pERK1/2-ERK1/2, (F) Cyclin D1, (G) CDK4 
protein expression. * p<0.05 E vs. C or T and ^ p<0.05 E+T vs. E.  
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Figure 4:  
Effect of trastuzumab on the antiproliferative response to TGFB1. (A) Representative images of 
immunofluorescence labelling for HER2 in GH3 and CaCO2 (positive control) cell lines. White arrowheads 
indicate the expression of the receptor at the plasma membrane. Scale bar 10um. Correlative Light and 
Electron Microscopy (CLEM): [1] Immunofluorescence images for HER2 detection in ultrathin cryo-sections 
of GH3 cells (scale bar 10um). [2] CLEM overlay of TEM and the corresponding FLM image. [3] TEM images 
for the whole section and, at higher magnification, the immuno-gold labelling for selected regions (a, b) 
shown by white boxes. Gold particles are indicated by black arrows. Cell proliferation analysis in GH3 cells, 
which were treated with TGFB1 (4 ng/ml), Trastuzumab (Trast, 100 mM) or the combination of both factors 
for 24 h. (B) Representative flow cytometry histograms and quantitative analysis of the proliferation-
associated protein Ki67. (C) Representative micrographs and quantification of BrdU uptake. *p<0.05 TGFB1 
or Trast vs. C, and ^p<0.05 TGFB1+Trast vs. TGFB1 or Trast. TGFB1 and MAPK-ERK1/2 signaling pathway 
analysis. Western blot panels and relative quantification of (D) pSMAD2/3-TSMAD2/3 and (E) pERK1/2-
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ERK1/2 expression from GH3 cell cultures treated with TGFB1, Trastuzumab or their combination for 30 min. 
(F) Immunoprecipitation (IP) of pSMAD2/3 and pERK1/2 and TBRI immunodetection in total cell extracts of 
GH3 cell cultures, untreated and treated for 30 min with Trastuzumab, TGFB1 or their combination. Input: 
TBRI or pERK1/2 or pSMAD2/3 antibody recognized the antigen in the total cell culture lysate.  
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Figure 5.  
Model for the cross talk of HER2/ERK1/2 with TGFβ1/SMAD pathways in pituitary GH3 cells. Blocking HER2 
by trastuzumab inhibits pituitary tumor growth and modulates HER2/ERK1/2 signaling, and consequently the 
anti-mitogenic TGFB/TBR/SMAD signaling. The HER2/ERK1/2 pathway impinges on the TGFβ1/SMAD2/3 
signaling, thereby modulating SMAD2/3 phosphorylation. The association of SMAD2/3-ERK1/2 inhibits the 
TβRI induced- SMAD2/3 activation, thus counteracting the antimitogenic effect of TGFβ1.  
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